Media Articleshttp://www.i-mak.org/media-articles/2010-04-04T01:29:50ZSquarespacehttp://www.i-mak.org/media-articles/2010/4/3/when-medical-patents-weaken-health-care.htmlI-Mak2010-04-04T01:25:37Z2010-04-04T01:25:37ZAn op-ed in the Huffington Post on April 1, 2010.

]]>http://www.i-mak.org/media-articles/2009/9/24/nyu-law-magazine-profiles-priti-radhakrishnan.htmlI-Mak2009-09-24T19:14:58Z2009-09-24T19:14:58ZTo read "Medicines Robin Hood: Priti Radhakrishnan gives the poor access to lifesaving drugs", NYU Law Magazine's profile on I-MAK Co-Director, click HERE.

]]>http://www.i-mak.org/media-articles/2009/9/23/scripnewscom-covers-tahir-amin-on-expert-patent-review.htmlI-Mak2009-09-23T21:26:57Z2009-09-23T21:26:57Z"The use of outside experts for reviewing patents could prevent the granting of unmerited patents and high drug prices in many developing countries. This is the view of Tahir Amin, co-Director of the Initiative for Medicines, Access & Knowledge (I-MAK), which helped prepare a pre-grant patent opposition to Gilead's AIDS treatment, Viread (tenofovir disoproxil fumarate), on behalf of Indian patient groups. Read more.

]]>http://www.i-mak.org/media-articles/2009/2/28/enforcement-creative-rd-financing-priority-issues-for-public.htmlI-Mak2009-02-28T01:34:53Z2009-02-28T01:34:53Z“Enforcement will dominate everything” in 2009, said Tahir Amin of the Intitiative for Medicines, Access & Knowledge (I-MAK) in New York. The use of the term “counterfeit” in reference to enforcement efforts, with its connotations of trademark law, will be “one of the major battlegrounds.” Read the full story here.

]]>http://www.i-mak.org/media-articles/2009/2/12/echoing-greens-featured-2008-fellows.htmlI-Mak2009-02-12T21:25:13Z2009-02-12T21:25:13ZIn its latest newsletter, Echoing Green features the founders of I-MAK.

]]>http://www.i-mak.org/media-articles/2009/2/10/i-mak-working-towards-improving-drug-access.htmlI-Mak2009-02-10T23:10:34Z2009-02-10T23:10:34ZBased in New York, I-MAK harnesses the best legal and scientific talent from across the world to help develop the best case possible to protect the public from companies misusing patent regulations and blocking access to cheap drugs.

]]>http://www.i-mak.org/media-articles/2009/1/19/dgoodrcom.htmlI-Mak2009-01-19T17:22:34Z2009-01-19T17:22:34ZI-MAK's Director of Treatment Access, Priti Radhakrishnan, was profiled on http://dgoodr.com/ this week.

]]>http://www.i-mak.org/media-articles/2009/1/8/generic-drugs-the-other-drug-war.htmlI-Mak2009-01-08T06:54:26Z2009-01-08T06:54:26ZCompulsory license use requires a certain amount of political will, says Priti Radhakrishnan, director of I-Mak, a health advocacy group looking at drug innovation and access, who notes that even threatening to issue a compulsory license can lead to significant backlash.

]]>http://www.i-mak.org/media-articles/2009/1/8/i-mak-works-to-make-drugs-affordable-for-the-poor.htmlI-Mak2009-01-08T03:46:53Z2009-01-08T03:46:53Z
When drug patents are misused or misapplied it can put vital medications out of reach for the poor, say Priti Radhakrishnan and Tahir Amin, the husband-and-wife co-founders of New York-based I-MAK (Initiative for Medicines, Access and Knowledge).

]]>http://www.i-mak.org/media-articles/2008/12/15/the-women-of-poptech.htmlI-Mak2008-12-15T02:52:05Z2008-12-15T02:52:05ZFive women who participated in Pop!Tech were featured in the Fringehog blog for the work that they do, including I-MAK Director of Treatment Access, Priti Radhakrishnan.

]]>